We believe that increased utilization of GLP-1s to treat obesity will bring many new people into the healthcare funnel, activating them to see their primary care physicians as they strive for weight loss and other medical health. Image courtesy of ResMed ResMed has been tracking the impact of GLP-1s through a de-identified patient analysis using an overlap of its own data and third-party claims data, Farrell said during the earnings call
In one trial, about 66 per cent of people on trizepatide lost more than 10 per cent of their body weight in one year, compared to 41 per cent on semaglutide
No nutrient works in a vacuum
En este grupo, el uso de Ozempic se tradujo en un descenso drstico de los problemas de adicciones que requeran tratamiento urgente, pero tambin se vio una menor tasa de ingresos hospitalarios, una menor mortalidad relacionada con las drogas, una cada en las sobredosis e, incluso, una reduccin significativa en la ideacin y los intentos suicidas
Whether the jump from dual to triple proves as significant in large-scale Phase 3 data as the jump from single to dual remains one of the most important questions in the field
These drugs mimic the action of glucagon-like peptide-1 (GLP-1), a naturally occurring hormone in the body that plays a key role in regulating blood sugar levels, satiety, and digestion
